J&J/Bayer to pursue secondary CV prevention in ACS label for Xarelto
This article was originally published in Scrip
Executive Summary
Johnson & Johnson and its partner Bayer Healthcare Pharmaceuticals have said they are planning to file for approval of the oral Factor Xa inhibitor, Xarelto (rivaroxaban), in the additional indication of secondary prevention of cardiovascular events in patients with acute coronary syndrome (ACS) by the end of this year.